Colgate-Palmolive (NYSE:CL) Reaches New 12-Month High – Should You Buy?

Colgate-Palmolive Company (NYSE:CL – Get Free Report) shares hit a new 52-week high during mid-day trading on Monday. The company traded as high as $101.26 and last traded at $101.2930, with a volume of 982,436 shares traded. The stock had previously closed at $99.67.

Key Colgate-Palmolive News

Here’s some of the latest news about CL:

  • Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $3.91 from $3.85 and its FY2027 and FY2028 forecasts to $4.06 and $4.38, respectively. It also lifted estimates for several quarters, including Q3 2028. The revisions point to improving earnings expectations, although the FY2026 forecast remains just below the $3.92 consensus. Zacks Research Has Bullish Forecast for CL FY2026 Earnings
  • Neutral Sentiment: A comparison with Kimberly-Clark highlighted Colgate-Palmolive’s leading oral-care position and pet-nutrition business as potential growth strengths, but offered no new company-specific financial announcement. Colgate-Palmolive vs. Kimberly-Clark: Which Household Name Deserves Your Investment Dollars?
  • Negative Sentiment: Zacks also trimmed some quarterly estimates, including Q1 and Q2 2027 and Q1 and Q2 2028, suggesting expectations are not uniformly improving. Separately, an executive vice president sold $401,677 of CL shares; insider selling can weigh on sentiment, though the report provides no context on the transaction. Insider Selling: Colgate-Palmolive EVP Sells $401,677.00 in Stock

Analyst Ratings Changes

A number of research firms recently commented on CL. Evercore upped their price objective on shares of Colgate-Palmolive from $100.00 to $101.00 and gave the company an “outperform” rating in a research report on Thursday, October 8th. UBS Group boosted their price objective on shares of Colgate-Palmolive from $106.00 to $112.00 and gave the stock a “buy” rating in a research report on Monday, November 2nd. Barclays raised their price target on Colgate-Palmolive from $87.00 to $95.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 3rd. Jefferies Financial Group restated a “hold” rating and set a $89.00 price objective (up from $88.00) on shares of Colgate-Palmolive in a research note on Monday, August 3rd. Finally, Morgan Stanley boosted their target price on Colgate-Palmolive from $104.00 to $111.00 and gave the stock an “overweight” rating in a report on Monday, November 2nd. Thirteen analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat.com, Colgate-Palmolive presently has an average rating of “Moderate Buy” and an average price target of $101.22.

View Our Latest Research Report on CL

Colgate-Palmolive Trading Up 1.8%

The company has a debt-to-equity ratio of 11.23, a current ratio of 0.96 and a quick ratio of 0.63. The business’s 50-day moving average price is $90.94 and its two-hundred day moving average price is $90.29. The company has a market capitalization of $80.67 billion, a price-to-earnings ratio of 39.80, a P/E/G ratio of 4.51 and a beta of 0.31.

Colgate-Palmolive (NYSE:CL – Get Free Report) last issued its quarterly earnings results on Friday, October 30th. The company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.93 by $0.04. The business had revenue of $5.37 billion during the quarter, compared to analysts’ expectations of $5.34 billion. Colgate-Palmolive had a return on equity of 607.88% and a net margin of 9.65%. The firm’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.91 earnings per share. Research analysts predict that Colgate-Palmolive Company will post 3.92 earnings per share for the current year.

Colgate-Palmolive Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 13th. Shareholders of record on Tuesday, October 20th were issued a $0.53 dividend. The ex-dividend date of this dividend was Tuesday, October 20th. This represents a $2.12 annualized dividend and a yield of 2.1%. Colgate-Palmolive’s payout ratio is currently 83.14%.

Insider Buying and Selling

In other news, COO Panagiotis Tsourapas sold 19,938 shares of the company’s stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $98.74, for a total transaction of $1,968,678.12. Following the completion of the sale, the chief operating officer directly owned 9,111 shares in the company, valued at approximately $899,620.14. This represents a 68.64% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Hazlin sold 23,376 shares of the stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $99.15, for a total value of $2,317,730.40. Following the sale, the insider directly owned 27,021 shares in the company, valued at approximately $2,679,132.15. This trade represents a 46.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 77,414 shares of company stock valued at $7,613,786. 0.43% of the stock is owned by insiders.

Institutional Trading of Colgate-Palmolive

A number of institutional investors and hedge funds have recently made changes to their positions in CL. State Street Corp raised its stake in shares of Colgate-Palmolive by 97.4% during the 2nd quarter. State Street Corp now owns 94,195,992 shares of the company’s stock valued at $8,635,889,000 after purchasing an additional 46,476,510 shares during the period. Bank of New York Mellon Corp raised its stake in Colgate-Palmolive by 8.1% in the second quarter. Bank of New York Mellon Corp now owns 13,532,417 shares of the company’s stock valued at $1,240,652,000 after purchasing an additional 1,010,872 shares in the last quarter. First Eagle Investment Management LLC raised its position in shares of Colgate-Palmolive by 1.1% during the 2nd quarter. First Eagle Investment Management LLC now owns 8,205,699 shares of the company’s stock valued at $752,298,000 after buying an additional 88,917 shares in the last quarter. Bank of America Corp DE raised its position in Colgate-Palmolive by 17.4% during the first quarter. Bank of America Corp DE now owns 6,637,597 shares of the company’s stock valued at $565,722,000 after purchasing an additional 986,063 shares in the last quarter. Finally, Amundi raised its holdings in shares of Colgate-Palmolive by 19.9% during the 2nd quarter. Amundi now owns 6,218,257 shares of the company’s stock valued at $570,090,000 after buying an additional 1,033,918 shares in the last quarter. Institutional investors own 80.41% of the company’s stock.

Colgate-Palmolive Company Profile

(Get Free Report)

Colgate-Palmolive is a global consumer products company whose business spans oral care, personal care, home care and pet nutrition. Its products include toothpaste, toothbrushes, mouthwashes, soaps, shampoos, cleaning products and pet food. The company’s best-known brands include Colgate, Palmolive, elmex, Softsoap, Ajax and Hill’s Pet Nutrition. It sells products through retail and other channels in markets around the world. Founded in 1806 by William Colgate as a soap and candle business in New York City, the company has grown into an international manufacturer of household and personal care products.

Recommended Stories

Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.